Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111202 | 0.84 | AKR1C4 (0.54) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL31460347 | 0.83 | THRB (0.44) | CYP3A4TPMTTSHRCASP1SMN1; SMN2 | |
| SCHEMBL366927 | 0.83 | CYP3A4 (0.44) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Urea SCHEMBL29192961 | 0.82 | AKR1C4 (0.48) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1301827 | 0.81 | AKR1C4 (0.52) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL5878784 | 0.81 | AKR1C4 (0.52) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28392002 | 0.81 | AKR1C4 (0.52) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Hydrochloric Acid SCHEMBL2512939 | 0.81 | AKR1C4 (0.52) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1398113 | 0.79 | KEAP1 (0.41) | CYP3A4TSHRHPGDCYP2C19TDP1 | |
| SCHEMBL31057404 | 0.79 | KDM4E (0.41) | CYP3A4AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1690040-A | 3,5-dichloroaniline preparing process | YANCHENG GUANGXIN CHEMICAL CO (CN) | 2005-11-02 | — | — | CN | claimed |
| US-3931300-A | Process for the production of dichlorobenzoic acids | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | claimed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119487031-A | Tryptanthrin derivatives and uses thereof | 威森特生物公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-0206323-A1 | 2-Oxy-4H-3,1-benzoxazin-4-one derivatives and related compounds | SYNTEX (U.S.A.) INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0104389-B1 | QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE CONTROL OF UNDESIRED PLANT GROWTH | BASF Aktiengesellschaft (DE) | 1986-07-16 | — | — | EP | disclosed |
| US-4587339-A | USED TO COLOR PLASTICS, PAINTS, AND INKS | SUN CHEMICAL CORPORATION (US) | 1986-05-06 | — | — | US | disclosed |
| US-4582902-A | AZO-METHINE NICKEL-COMPLEXED PIGMENTS; PAINTS; PLASTICS; LACQUERS; PHOTSTABILITY | SUN CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| US-4581450-A | INTERMEDIATES FOR PIGEMENTS | SUN CHEMICAL CORPORATION (US) | 1986-04-08 | — | — | US | disclosed |
| US-4508899-A | COLORFAST RED-ORANGE-YELLOW ORGANIC PIGMENT | SUN CHEMICAL CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
| EP-0104389-A2 | Quinoline derivatives, process for their preparation and their use in the control of undesired plant growth | BASF Aktiengesellschaft (DE) | 1984-04-04 | — | — | EP | disclosed |
| US-3971741-A | DISPERSION PIGMENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3931300-A | Process for the production of dichlorobenzoic acids | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | CYP3A4 1477/4885AKR1C4 3453/4885AKR1C3 3366/4885 |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | CYP3A4 1451/4885AKR1C4 3816/4885AKR1C3 3315/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | CYP3A4 1273/4885AKR1C4 3681/4885AKR1C3 3154/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | CYP3A4 3573/4885AKR1C4 2335/4885AKR1C3 2681/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | CYP3A4 2837/4885AKR1C4 2866/4885AKR1C3 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.